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Background: Opioid-induced constipation (OIC) is
a common adverse effect associated with opioid use.
Naloxegol is a PEGylated derivative of naloxone in
clinical development as a once-daily oral treatment
of OIC.
Objectives: A thorough QT/QTc study was con-
ducted, according to International Conference on
Harmonisation E14 guidelines, to characterize the
effect of naloxegol on cardiac repolarization.
Methods: In this randomized, positive- and placebo-
controlled crossover study, healthy men received a
single dose of naloxegol 25 mg (therapeutic dose),
naloxegol 150 mg (supratherapeutic dose), moxiﬂox-
acin 400 mg (positive control), or placebo in 1 of
4 sequences (Williams Latin square design). The
washout time between treatment periods was at least
5 days. Digital 12-lead ECGs were recorded at base-
line and at 10 time points over 24 hours after dosing
in each treatment period. QT intervals were corrected
for heart rate using the Fridericia formula (QTcF) and
the Bazett formula (QTcB).
Results: A total of 52 subjects were enrolled (mean
age, 28 years), and 45 received all 4 treatments. The
placebo-corrected, baseline-adjusted, mean increases in
QTcF with naloxegol 25 and 150 mg were botho5 msec
at each time point, and all upper limits of the 2-sided
90% CI were o10 msec. Similar ﬁndings were observed
using QTcB; the upper limits of the 2-sided 90% CI were
o10 msec at all time points after dosing with naloxegol
25 or 150 mg. With moxiﬂoxacin 400 mg, mean QTcF
was increased by a maximum of 11.1 msec (90% CI,
9.3–12.9 msec), supporting assay sensitivity.
Conclusion: Naloxegol at 25 and 150 mg was not
associated with QT/QTc interval prolongation in these
healthy men, and at the proposed therapeutic dose of
25 mg/d, naloxegol is not expected to have a clinically
relevant effect on cardiac repolarization in patients with1876OIC. ClinicalTrials.gov identiﬁer: NCT01325415. (Clin
Ther. 2013;35:1876–1883)
& 2013 The Authors. Published by Elsevier, Inc.
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INTRODUCTION
Opioids are effective analgesics and are commonly
used to treat moderate to severe pain.1,2 Opioid-
induced constipation (OIC) is one of the most com-
mon and often debilitating adverse effects associated
with opioid use.3 Depending on the population
studied and the deﬁnitions used, OIC may occur in
15% to 81% of patients receiving opioids.4–8
Common treatments for OIC include laxatives and
stool softeners; however, these are ineffective in many
patients.3,9 Opioid antagonists possibly represent a
more effective alternative to laxatives for the treat-
ment of OIC.9 In particular, opioid antagonists that
are restricted to the periphery should antagonize the
actions of opioids in the gastrointestinal tract without
affecting their analgesic effects or causing other
central nervous system (CNS) opioid withdrawal
effects. Naloxegol is a PEGylated derivative of nalox-
one that is in clinical development as a once-daily oral
treatment for OIC.10 Naloxegol was designed to act as
a peripheral opioid antagonist of m-opioid receptors
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In a Phase 2 study, naloxegol was associated with a
signiﬁcantly increased frequency of spontaneous
bowel movements in patients with OIC, without a
reduction in opioid-mediated analgesia.11
Many structurally diverse drugs have been shown to
delay cardiac repolarization, demonstrated by a pro-
longed QT/QTc interval, which can lead to cardiac
arrhythmias.12 This is particularly important in ind-
ividuals receiving pain medication because some
opioids (eg, methadone) can cause prolongation of
the QT/QTc interval.13 The International Conference
on Harmonisation (ICH) E14 guidelines recommend
that all nonarrhythmic compounds undergo clinical
evaluation and characterization of ventricular repolari-
zation (QT/QTc) changes by means of a thorough
QT/QTc study early in the course of their clinical
development.14 The primary objective of this study was
to evaluate the effects of 2 different single doses of
naloxegol (25 and 150 mg, a therapeutic and a
supratherapeutic dose, respectively) on the change in
time-matched heart rate–corrected QT intervals ac-
cording to the Fridericia method (QTcF) compared
with placebo. Secondary objectives included evaluation
of the effect of a single dose of moxiﬂoxacin 400 mg
(positive control) on time-matched and placebo-
corrected changes in QTcF.
SUBJECTS AND METHODS
This study was designed and monitored in accord-
ance with ethical principles of the Declaration of
Helsinki and Good Clinical Practice as deﬁned by the
ICH. An independent institutional review board
(MidLands Independent Review Board, Overland
Park, Kansas) approved the protocol before trial
commencement, and all subjects gave written in-
formed consent. The study was conducted at a single
study center (Quintiles Phase I Unit, Overland Park,
Kansas).
Inclusion and Exclusion Criteria
Study volunteers were healthy, nonsmoking men
aged 18 to 50 years with a body mass index between
18 and 30 kg/m2 and weight between 50 and 100 kg.
Key exclusion criteria were an abnormal ECG; history
of arrhythmia; QTcF 4450 msec; abnormal vital
signs; history or presence of cardiac, psychiatric,
gastrointestinal, hepatic, or renal disease; excessive
consumption of caffeine-containing products withinDecember 201348 hours of each treatment period; history of or
suspected drug or alcohol abuse; and use of any
prescribed or over-the-counter medication within
2 weeks before the administration of the investiga-
tional drug.
Study Design
This randomized, 4-period, 4-treatment, single-
dose crossover study consisted of 6 visits. During
each 2-day treatment period, each volunteer received
1 of the 4 treatments in 1 of 4 treatment sequences,
applying a Williams Latin square design in a double-
blind fashion determined by a randomization sched-
ule. The wash-out time between treatment periods was
at least 5 days.
Subjects were screened within 30 days before
randomization. Each subject received the following
4 treatments, administered in the order prescribed by
the sequence to which the subject had been randomly
assigned: naloxegol 25 mg, naloxegol 150 mg, open-
label moxiﬂoxacin 400 mg, and placebo. Subjects
underwent a 10-hour fast before dosing, and no food
intake was allowed until 4 hours after dosing.
Tolerability Assessment
Vital sign measurements, 12-lead safety ECGs
printed on paper, physical examinations, and safety
laboratory analyses involving routine hematology,
serum chemistry, and urinalysis were obtained and
reviewed by the investigator during the study and
at a follow-up examination 7 to 10 days after the
last treatment period. The subjects stayed at the
phase 1 unit during all 4 dosing visits and were
continuously monitored with ECG telemetry (real-
time ECG display) from 30 minutes predose through
24 hours postdose. All adverse events (AEs) were
evaluated by the investigator and characterized with
respect to intensity, duration, relationship to study
drug, and outcome.
Pharmacodynamic Measurements
Twelve-lead continuous digital ECG (dECG) recor-
dings were obtained using a Schiller Cardiovit CS-200
recorder (Schiller AG, Baar, Switzerland). The analy-
ses of all dECGs were performed at the AstraZeneca
ECG Centre (AstraZeneca ECG Core Lab, Mölndal,
Sweden) in a fully blinded mode (sequence, treatment,
time, and subject identiﬁer) using the EClysis System
(ECG Analysis, AstraZeneca proprietary tool,1877
Clinical TherapeuticsMölndal, Sweden), an automated reading method for
dECG intervals allowing manual adjudication (ie, a
semiautomatic analysis).15,16 Recordings were taken for
20 minutes at baseline and then for 5 minutes at 0.5, 1,
1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose using the
same ECG machine at all time points in an individual
subject, if possible. All dECG recordings were obtained
after at least 10 minutes of rest in bed in the same
supine body position at all time points and just before
blood sample collections for pharmacokinetic (PK)
assessments and blood pressure measurements.
The primary variable in this study was QTcF. The
lead V2 was used as the primary lead, and lead V5
was used as the back-up lead for all time points when
lead V2 was found to be unsuitable for analysis or
evaluation. The QT interval was measured (in milli-
seconds) from the onset of the QRS complex to the
end of the T wave. The end of the T wave was
determined with the help of a tangent of the T-wave
downslope crossing the isoelectrical line. With EClysis
software, the tangent was derived between the 20%
and 80% repolarization points of the T wave calcu-
lated from the top of the T wave to the isoelectrical
line.16 The Fridericia correction method for heart rate
is described subsequently. Other dECG-collected
or -derived variables were heart rate (HR) in beats
per minute; the RR interval, which is the time between
corresponding points on 2 consecutive R waves in
seconds; the PR interval, which is measured from the
onset of the P wave to the onset of the QRS complex
in milliseconds; the QRS duration, which is the
interval measured from the onset of the QRS com-
plex to the J point in milliseconds; and the QT interval
corrected for heart rate using the Bazett formula
(QTcB) in milliseconds. Ten-second dECGs were
extracted every 30 seconds from the predeﬁned 5- or
20-minute (baseline only) continuous recordings. The
extracted data were averaged to arrive at a mean value
for each time point. The QT interval was corrected for
RR interval to obtain QTc variables. The general
formula for QTc was QT/RRb, with QT intervals
expressed in milliseconds and the RR interval in
seconds. For QTcF, b ¼ 1/3; for QTcB, b ¼ 0.5.
Pharmacokinetic Measurements
Blood samples for PK analysis were collected
within 30 minutes before investigational drug admin-
istration and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and
24 hours following each treatment dose. AUC0–t,1878Cmax, Tmax were calculated for both naloxegol and
moxiﬂoxacin. Samples for determination of naloxegol
and moxiﬂoxacin concentrations in plasma were
analyzed by Covance Laboratories (Indianapolis,
Indiana) using HPLC-MS/MS.
Statistical Analysis
Assuming a 3-msec effect of naloxegol on QTcF, an
8-msec residual variability, and 20 postdose dECG
assessments (10 time points  2 treatments),
44 evaluable volunteers were needed to provide490%
power to conclude no effect on QTcF at or above the
10-msec threshold. The safety-analysis set consisted of
all subjects who received at least 1 dose of naloxegol,
moxiﬂoxacin, or placebo and for whom any postdose
data were available. The pharmacodynamic analysis
set included all randomized subjects who received any
study treatment and had any evaluable pharmacody-
namic postdose data. The PK analysis set included all
randomized subjects who received at least 1 dose of
naloxegol or moxiﬂoxacin and had at least 1 postdose
PK measurement.
The analysis of change from baseline QTc was
performed using a linear mixed-effects repeated meas-
ures model with treatment, period, and time as ﬁxed
categorical effects and baseline QTc as a continuous
covariate; ﬁxed-effect interactions for period and time
and for treatment and time; volunteer within sequence
was treated as a random effect, and the within-
volunteer correlation was a ﬁrst-order autoregression
covariance structure.
For assessment of QTc prolongation, differences
for naloxegol 25 and 150 mg versus placebo were
statistically tested at each measurement time point,
based on the mixed model using least squares (LS)
mean differences and corresponding 2-sided 90% CI.
A negative study requires all upper conﬁdence limits
to be o10 msec.
For assessment of assay sensitivity, differences be-
tween moxiﬂoxacin versus placebo were statistically
tested, averaging across the 1- to 4-hour range, based
on the mixed model using LS mean differences and
corresponding 2-sided 90% CI. Establishing assay sensi-
tivity required that the lower limit of the CI be45 msec.
RESULTS
A total of 52 male subjects were randomized, and 45
received all 4 treatments. Twenty-eight subjects (54%)
were white; 22 (42%) were black; and 2 (4%) wereVolume 35 Number 12
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Figure 1. Placebo-corrected, baseline-adjusted,
LS mean differences in QTcF interval
versus sample time with single-dose
administration of naloxegol and mox-
ifloxacin in healthy men. LS ¼ least
squares; QTcF ¼ QT interval cor-
rected using the Fridericia formula.
C. Gottfridsson et al.Native American or Native Alaskan. The age of the
subjects ranged from 18 to 50 years (mean, 28 years;
median, 25 years); body mass index ranged between
19 and 30 kg/m2 (mean, 25 kg/m2; median, 24 kg/m2).
Seven subjects withdrew from the study: 1 subject was
removed for severe noncompliance with the protocol,
3 withdrew consent, and 3 were lost to follow-up.QTc Interval
The placebo-corrected, baseline-adjusted mean QTcF
for naloxegol 25 and 150 mg were botho5 msec at each
time point, and all upper limits of the 2-sided 90% CITable I. QTcF intervals with single-dose administration o
are maximum placebo-corrected, baseline-adjus
Parameter 25 mg (n
QTcF, msec
Mean 1.1
90% CI –0.6 to
Time from administration to maximum
absolute change from baseline in QTcF, h
2
QTcF ¼ QT interval corrected using the Fridericia formula.
December 2013were o10 msec (Figure 1). The maximum placebo-
corrected, baseline-adjusted mean change in QTcF was
1.1 msec at 2 hours after dosing with naloxegol 25 mg
and 3.1 msec with naloxegol 150 mg at both 1.5 and
2 hours after dosing (Table I). Similar ﬁndings were
observed using QTcB; the upper limit of the 2-sided
90% CI waso10 msec at all assessed time points after
dosing with naloxegol 25 or 150 mg.
With moxiﬂoxacin 400 mg versus placebo, the
largest placebo-corrected, baseline-adjusted mean
change from baseline in QTcF was an increase of
11.1 msec (90% CI, 9.3–12.9 msec), which occurred
at 3 and 4 hours after dosing (Figure 1, Table I).
Assay sensitivity was demonstrated by comparing
moxiﬂoxacin versus placebo QTcF averaged over the
1- to 4-hour range after dosing, using the mixed-
effects repeated measures model. The lower limit of
the 2-sided 90% CI for the difference (9.6 msec) of
moxiﬂoxacin versus placebo in ΔΔQTcF over the
interval of 1 to 4 hours postdose was 45 msec,
thereby establishing assay sensitivity.
QTc Interval Increase From Baseline and
Absolute QTc Interval Prolongation
Changes in QTcF from baseline to the observed
maximum did not exceed 30 msec at any time point
over the 24-hour period after dosing with naloxegol
25 or 150 mg or with placebo (Figure 2). One subject
receiving moxiﬂoxacin had a QTcF increase from
baseline between 30 and 60 msec at 6 hours
postdose. There were no subjects with absolute
QTcF values 4450 msec.f naloxegol and moxifloxacin in healthy men. Values
ted means.
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Figure 2. Shift from baseline to the maximum
observed QTcF interval by treatment
with single-dose administration of na-
loxegol, moxifloxacin, or placebo in
healthy men. QTcF ¼ QT interval
corrected using the Fridericia formula.
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Changes in HR and RR, QT, PR, and QRS
intervals were similar between naloxegol 25 and
150 mg and placebo. No clinically important cha-
nges in T-wave morphology were observed in
this study.Table II. Pharmacokinetic parameters with single-dose
healthy men. Values are geometric means (%C
Parameter
Nalox
25 mg (n ¼ 51)
AUC0–t, ng  h/mL
Unadjusted 156 (38.8)
Dose normalized 6.25 (38.7)
Cmax, ng/mL
Unadjusted 37.7 (48.0)
Dose normalized 1.51 (48.0)
Tmax, median (range), h 1.52 (0.52–4.03)
1880Pharmacokinetic Properties
Naloxegol was rapidly absorbed following oral
administration, with a median Tmax of 1 and
1.5 hours with the high and low doses, respectively
(Table II). The geometric means of the dose-
normalized PK parameters (AUC0–t and Cmax) for
naloxegol 25 and 150 mg were similar, suggesting
dose proportionality over the dose range. The plasma
concentrations and PK parameters of moxiﬂoxacin
were similar to values previously reported.17
Tolerability
There were no deaths, serious AEs, or discontinua-
tions of naloxegol due to AEs in the study. At least
1 AE was reported in 4 subjects (8%) with naloxegol
25 mg, in 9 subjects (18%) with naloxegol 150 mg, in
8 subjects (17%) with moxiﬂoxacin 400 mg, and in
9 subjects (19%) with placebo. Most AEs were mild,
not considered by the investigator as related to
naloxegol, and resolved at study end. Naloxegol was
not associated with clinically relevant changes in
blood pressure, other vital signs, or laboratory values.
DISCUSSION
Excessive prolongation of cardiac repolarization in-
dicated by QT interval lengthening/instability can lead
to a life-threatening polymorphic ventricular tachy-
cardia—torsades de pointes—which has a chara-
cteristic ECG pattern and can potentially cause
sudden cardiac death.18 A number of structurally
diverse noncardiac drugs can cause QT/QTc intervaladministration of naloxegol and moxifloxacin in
V) unless otherwise noted.
egol
Moxiﬂoxacin 400 mg
(n ¼ 48)150 mg (n ¼ 49)
921 (36.6) 19,800 (15.1)
6.14 —
291 (47.4) 1960 (27.3)
1.94 —
1.02 (0.52–4.02) 1.52 (0.52–6.03)
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all nonarrhythmic compounds undergo clinical eva-
luation for QT interval prolongation.14 The objective
of this study was to assess the potential for naloxegol to
prolong ventricular repolarization in human subjects at
both therapeutic and supratherapeutic doses, and the
results show that this is a negative thorough QT/QTc
study based on the ICH E14 guidelines.14
In the primary comparisons of QTcF for naloxegol
versus placebo, all upper limits of the 90% CI for the
difference in mean QTc interval between naloxegol
25 or 150 mg and placebo were o10 msec at all time
points. Moreover, the baseline-adjusted, placebo-
corrected mean changes in QTcF for both naloxegol
doses were o5 msec at all time points.
Assay sensitivity was established with the positive
control, moxiﬂoxacin. The PK results of this study
demonstrated that adequate exposure was achieved for
the therapeutic and supratherapeutic doses of naloxegol
and for moxiﬂoxacin in these healthy subjects. The PK
data together with the assay sensitivity results allowed
for the valid assessment of QT effects of naloxegol.
No tolerability concerns for naloxegol were identiﬁed
in this study up to a supratherapeutic dose of 150 mg.
The proportions of subjects who experienced an AE were
similar across treatment groups, and most AEs were
judged to be unrelated to treatment. Moreover, there
were no discontinuations from the study due to AEs.
Thus, naloxegol appeared to be generally well tolerated.
Opioids are effective and commonly used in the
treatment of severe pain.3,13 However, their use is often
limited by adverse effects that can sometimes lead
patients to reduce or abandon opioid therapy.5,6,8
OIC is a common adverse effect during long-term
opioid use,3 and OIC signiﬁcantly affects patients’
quality of life and daily activities5 to the extent that
some patients would rather endure the pain than the
constipation that accompanies opioid use.19
Treatments for OIC include laxatives and stool softe-
ners; however, these are ineffective in many patients3,9
and do not affect the underlying cause of OIC—
activation of opioid receptors in the gastrointestinal
tract that decrease gastric motility, intestinal propul-
sion, and intestinal secretion.20 Opioid antagonists
represent a possible alternative to laxatives for the
treatment of OIC.9 However, opioid antagonists that
penetrate the CNS may generate central effects, leading
to inadequate pain control.9 Opioid antagonists that
are restricted to the periphery should antagonize theDecember 2013activity of opioids in the gastrointestinal tract without
affecting their analgesic effects. Naloxegol is a PEGy-
lated derivative of naloxone in clinical development as
a once-daily oral treatment for OIC.10 Naloxegol was
designed to act as a peripheral opioid antagonist of
m-opioid receptors because the PEG moiety markedly
reduces its capacity to cross the blood-brain barrier and
enter the CNS.10 In a Phase 2 study, naloxegol restored
gastrointestinal function by increasing the frequency of
spontaneous bowel movements in patients with OIC,
without reversing or reducing opioid-mediated
analgesia.11
Individuals receiving opioid therapy for pain man-
agement are predominantly white, married women
aged 440 years21–24 with numerous comorbidities,
including depression and other mental health disor-
ders.22,25 Concomitant drug use in these individuals is
high and may include antidepressants, hypno-
tics, sedatives, antiemetics, and other psychoactive
drugs.21–23,26,27 Because some members of these drug
classes (eg, tricyclic antidepressants) as well as meth-
adone (commonly used as pain medication in the
United States28 but infrequently in Europe29) are
known to prolong the QT interval,12,13,18 it is im-
portant that naloxegol, a drug in development for the
proposed indication of OIC,10 had no effect on QT
interval prolongation.
CONCLUSION
Naloxegol at doses up to 150 mg was not associated
with QT/QTc interval prolongation in these healthy
male subjects. Placebo-corrected, baseline-adjusted
mean QTcF values for naloxegol were o5 msec at
all time points, and there were no absolute QTc
interval increases 430 msec with naloxegol. Based
on these data, naloxegol at the proposed therapeutic
dose of 25 mg/d does not have a clinically relevant
effect on cardiac repolarization in patients with OIC.
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